Hermetica Superfood Encyclopedia
The Short Answer
Mackerel oil delivers eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which incorporate into cellular phospholipid bilayers and suppress pro-inflammatory eicosanoid synthesis by competing with arachidonic acid, while simultaneously activating PPARα/γ receptors and GPR120 to modulate gene expression governing inflammation and lipid metabolism. Supercritical CO₂-extracted mackerel skin oil contains up to 12.56% EPA and 15.01% DHA of total lipids, with atherogenic indices as low as 0.72, supporting its role in cardiovascular risk reduction and neurological membrane integrity.
CategoryExtract
GroupMarine-Derived
Evidence LevelPreliminary
Primary Keywordmackerel oil omega-3 benefits
Mackerel Oil — botanical close-up
Health Benefits
**Cardiovascular Risk Reduction**: EPA and DHA lower atherogenic index (AI: 0
72–0.93) and thrombogenic index (TI: 0.75–0.92) in mackerel oil fractions, reflecting improved lipid profiles, reduced platelet aggregation, and enhanced endothelial function that collectively decrease risk of atherosclerosis and thrombotic events.
**Anti-Inflammatory Action**
EPA competes directly with arachidonic acid for cyclooxygenase and lipoxygenase enzymes, shifting eicosanoid production from pro-inflammatory prostaglandin E2 and leukotriene B4 toward less potent series-3 prostaglandins and series-5 leukotrienes, resulting in measurable reductions in systemic inflammatory markers.
**Neurological and Cognitive Support**
DHA constitutes approximately 30–40% of fatty acids in neuronal phospholipid membranes and is essential for synaptic plasticity, neurotransmitter receptor function, and myelination; adequate DHA status is associated with improved cognitive development in infants and slower cognitive decline in aging populations.
**Immunomodulation**
GPR120 activation by DHA on macrophages and dendritic cells inhibits NF-κB and NLRP3 inflammasome signaling, reducing secretion of TNF-α, IL-1β, and IL-6, thereby modulating both innate and adaptive immune responses without global immunosuppression.
**Lipid Profile Improvement**
EPA and DHA reduce hepatic VLDL triglyceride synthesis and secretion via PPARα-mediated upregulation of β-oxidation genes, contributing to clinically meaningful reductions in serum triglycerides (typically 15–30% at doses of 2–4 g/day EPA+DHA) while modestly raising HDL cholesterol.
**Anti-Arrhythmic Effects**
DHA stabilizes cardiomyocyte ion channels, particularly voltage-gated sodium and L-type calcium channels, reducing membrane excitability and susceptibility to ventricular arrhythmias; this mechanism is thought to underlie epidemiological associations between fish consumption and reduced sudden cardiac death.
**Joint and Musculoskeletal Health**
EPA-derived resolvins and protectins act as pro-resolving mediators that actively terminate inflammatory cascades in synovial tissue, with clinical evidence from broader fish oil trials showing reductions in joint stiffness and tender joint counts in rheumatoid arthritis patients.
Origin & History
Natural habitat
Mackerel species of the genus Scomber, including Atlantic mackerel (Scomber scombrus) and Japanese Spanish mackerel (Scomberomorus niphonius), are epipelagic, schooling fish distributed across temperate and subtropical waters of the North Atlantic, Mediterranean, Pacific, and East Asian seas, including Korean, Japanese, and Chinese coastal regions. These cold-water, oily fish accumulate high concentrations of omega-3 polyunsaturated fatty acids in their muscle and skin tissues, particularly during periods of high zooplankton consumption. Mackerel oil is commercially extracted from whole fish, filleting by-products, skin, and viscera, with harvest occurring year-round but peaking in autumn when lipid content is highest.
“Mackerel has been a cornerstone of coastal diets in Japan, Korea, China, and Mediterranean Europe for centuries, prized as an affordable, nutritionally dense oily fish and preserved by salting, smoking, and fermentation (e.g., Japanese shiokara, Korean godeungeo-jorim) long before the biochemical rationale for its omega-3 content was understood. In traditional East Asian medicine, oily fish consumption was associated with longevity, cardiovascular vitality, and mental clarity, with mackerel featured prominently in dietary prescriptions within Kampo (Japanese) and Traditional Korean Medicine frameworks as a strengthening food for the elderly and those with circulatory complaints. Mediterranean cultures incorporated mackerel into the traditional Mediterranean diet pattern, which was retrospectively associated with reduced cardiovascular mortality in the landmark Seven Countries Study initiated by Ancel Keys in the 1950s, providing early epidemiological support for marine oil consumption. The industrial extraction of mackerel oil as a discrete supplement ingredient is a modern development of the late 20th century, driven by the characterization of EPA and DHA by researchers including Ralph Holman and the clinical investigation of Greenlandic Inuit populations by Bang and Dyerberg in the 1970s, whose low cardiovascular disease rates despite high-fat diets prompted systematic investigation of marine omega-3s.”Traditional Medicine
Scientific Research
The clinical evidence base for omega-3 PUFAs broadly is extensive, with thousands of randomized controlled trials and numerous systematic reviews and meta-analyses; however, mackerel oil specifically from Scomber spp. lacks dedicated large-scale human RCTs with reported effect sizes and p-values, meaning most mechanistic and compositional data derive from analytical chemistry studies and preclinical models. Compositional research on supercritical CO₂-extracted Scomberomorus niphonius oil has characterized EPA (4.93–5.81%) and DHA (12.56–15.01%) concentrations across tissues, and atherogenic and thrombogenic index calculations provide indirect cardiovascular safety indicators, but these are not clinical outcome measures. Broader fish oil meta-analyses—most prominently the REDUCE-IT trial (n=8,179, icosapentaenoic acid ethyl ester 4 g/day) and STRENGTH trial (n=13,078)—demonstrate significant cardiovascular event reduction with high-dose EPA supplementation (HR 0.75, 95% CI 0.68–0.83 in REDUCE-IT), though these used pharmaceutical-grade EPA concentrates rather than mackerel-derived oil. The gap between general omega-3 evidence and mackerel-specific clinical data means the evidence score for mackerel oil as a distinct supplement form is conservatively rated, and dedicated RCTs using standardized mackerel oil extracts are needed to establish species- and matrix-specific efficacy.
Preparation & Dosage
Traditional preparation
**Crude Extracted Oil (Dietary/Food Grade)**
314–440 mg EPA+DHA per 100 g fish tissue; consumed as whole food rather than supplement
Whole mackerel or by-product oil providing approximately .
**Standard Fish Oil Softgels (Triglyceride Form)**
000 mg oil per capsule delivering approximately 180 mg EPA + 120 mg DHA; 1–3 capsules daily (300–900 mg EPA+DHA) for general health maintenance
Typical commercial dose of 1,.
**Supercritical CO₂ Concentrate**
000 mg concentrate provides 150–550 mg EPA+DHA
Yields 35–55% omega-3 content with higher EPA/DHA purity and reduced saturated fat; standardized to minimum 30% EPA+DHA; dose of 500–1,.
**Molecular Distillation Ethyl Ester Concentrate**
2–4 g EPA+DHA daily for cardiovascular risk reduction or hypertriglyceridemia
Up to 55% omega-3 ethyl esters; effective for pharmaceutical-grade supplementation at .
**Phospholipid-Bound Form**
DHA in phospholipid matrix (as naturally occurs in mackerel muscle tissue) demonstrates superior bioavailability versus triglyceride or ethyl ester forms at equivalent doses; preferred for neurological applications.
**PEF + Ultrasound-Assisted Extract**
Emerging processing technology yielding 30–41% PUFA content from mackerel by-products with enhanced oxidative stability; not yet widely commercially available.
**Cardiovascular Dose Range**
000 mg EPA+DHA daily based on extrapolated fish oil trial data; triglyceride-lowering effects are dose-dependent
1,000–4,.
**Timing**
2 g daily to minimize gastrointestinal effects
Take with meals containing dietary fat to enhance absorption; divide doses if taking >.
Nutritional Profile
Mackerel oil is composed primarily of lipids, with total PUFA content ranging from 14.99% to 29.15% of total fatty acids depending on extraction method and tissue source; EPA accounts for 4.93–5.81% and DHA for 12.56–15.01% in supercritical CO₂ extracts from Scomberomorus niphonius. Saturated fatty acids (SFAs) comprise approximately 35–40% of total lipids in extracted mackerel oil, with palmitic acid (C16:0) as the dominant SFA, while monounsaturated fatty acids (MUFAs), predominantly oleic acid (C18:1), constitute approximately 20–30%. Whole mackerel fillets (100 g) provide approximately 13–16 g total fat, 314–440 mg EPA+DHA, along with high-quality complete protein (~20 g), vitamin D (approximately 643–1006 IU), vitamin B12 (approximately 16 µg, exceeding daily requirements), selenium (~44 µg), and niacin. Bioavailability of EPA and DHA is enhanced when present in phospholipid form (as in intact fish muscle) compared to triglyceride or ethyl ester forms in supplements; co-ingestion with dietary fat further improves absorption by stimulating bile secretion and chylomicron formation.
How It Works
Mechanism of Action
EPA and DHA are incorporated into the sn-2 position of membrane phospholipids, displacing arachidonic acid and reducing substrate availability for cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX), thereby decreasing synthesis of pro-inflammatory prostaglandin E2, thromboxane A2, and leukotriene B4 while promoting production of less potent 3-series prostaglandins, 5-series leukotrienes, and specialized pro-resolving mediators including resolvins D and E series, protectins, and maresins. At the transcriptional level, EPA and DHA act as endogenous ligands for peroxisome proliferator-activated receptors alpha and gamma (PPARα/γ), activating gene programs that upregulate fatty acid β-oxidation, reduce expression of inflammatory cytokines (TNF-α, IL-6, IL-1β), and improve insulin sensitivity. DHA binds GPR120 (FFAR4) on immune cells and intestinal enteroendocrine cells, triggering β-arrestin-2-mediated internalization of TAB1, which prevents TAK1 activation and downstream NF-κB and JNK inflammatory signaling. Additionally, both fatty acids modulate membrane lipid raft composition and fluidity, altering Toll-like receptor 4 (TLR4) clustering and downstream MyD88-dependent signaling, contributing to reduced macrophage activation and lower circulating inflammatory burden.
Clinical Evidence
No mackerel-oil-specific randomized controlled trials with quantified clinical outcomes have been identified in the available literature, representing a meaningful evidence gap for this ingredient as a distinct supplement form. Clinical evidence is extrapolated from broader fish oil and omega-3 PUFA trials: the REDUCE-IT trial demonstrated a 25% relative risk reduction in major adverse cardiovascular events with high-dose EPA (4 g/day) versus placebo in high-risk patients, while meta-analyses of general fish oil supplementation consistently show 15–30% reductions in serum triglycerides at doses of 2–4 g EPA+DHA daily. Infant DHA supplementation trials have demonstrated improvements in visual acuity and cognitive indices, and rheumatoid arthritis RCTs with fish oil show reductions in tender joint counts and NSAID requirements compared to placebo. Confidence in mackerel oil specifically is moderate-to-low given the absence of species-specific trials; efficacy assumptions are derived from biochemically comparable marine oil sources and the well-characterized pharmacology of EPA and DHA regardless of fish source.
Safety & Interactions
At typical supplemental doses of 1–3 g EPA+DHA daily, mackerel oil and comparable fish oils are well tolerated; the most common adverse effects are minor gastrointestinal complaints including fishy aftertaste, eructation, nausea, and loose stools, which can be mitigated by enteric-coated formulations or refrigerated storage of capsules. The high PUFA content of mackerel oil renders it susceptible to lipid peroxidation and oxidative rancidity during extraction and storage, with autoxidation producing cytotoxic aldehydes including 4-hydroxy-2-hexenal; quality products should be stabilized with mixed tocopherols and stored in low-oxygen, light-protected conditions, and rancid oil should be discarded. Drug interactions of clinical significance include potentiation of anticoagulant and antiplatelet effects with warfarin, aspirin, clopidogrel, and other blood-thinning agents at high doses (≥3 g EPA+DHA/day), warranting INR monitoring; fish oil may also modestly lower blood pressure, potentially additive with antihypertensive medications. Contraindications include confirmed seafood or fish allergy; individuals with bleeding disorders, scheduled surgery within two weeks, or those on anticoagulation therapy should consult a physician before use; pregnancy and lactation are not contraindications—DHA is recommended at ≥200 mg/day during pregnancy for fetal neurodevelopment—but methylmercury content in whole fish warrants preference for purified, tested supplements.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Scomber scombrus oilScomberomorus niphonius oilJapanese Spanish mackerel oilEPA/DHA fish oilmarine omega-3 oilAtlantic mackerel oilMackerel Oil Vitamin D (Scomber scombrus)
Frequently Asked Questions
How much EPA and DHA does mackerel oil contain compared to other fish oils?
Supercritical CO₂-extracted mackerel oil (Scomberomorus niphonius) contains approximately 4.93–5.81% EPA and 12.56–15.01% DHA of total fatty acids, with total PUFA content ranging from 14.99–29.15% depending on extraction method and tissue source. This DHA concentration is comparable to or slightly higher than sardine and anchovy oils, making mackerel a competitive marine omega-3 source; standard fish oil supplements typically provide 180 mg EPA and 120 mg DHA per 1,000 mg capsule, though concentrated mackerel oil extracts can deliver significantly more.
What is the best form of mackerel oil supplement for absorption?
DHA and EPA in phospholipid form—as naturally occurring in mackerel muscle tissue—demonstrate superior bioavailability compared to triglyceride or ethyl ester forms at equivalent doses, because phospholipid-bound omega-3s are more efficiently incorporated into intestinal micelles and chylomicrons. For commercial supplements, re-esterified triglyceride concentrates are generally better absorbed than ethyl esters, and all forms should be taken with a fat-containing meal to stimulate bile secretion and optimize lymphatic uptake.
Is mackerel oil safe to take with blood thinners like warfarin?
At supplemental doses exceeding approximately 3 g EPA+DHA per day, mackerel oil and other fish oils can potentiate the anticoagulant and antiplatelet effects of warfarin, aspirin, and clopidogrel, increasing bleeding risk; this interaction is dose-dependent and less concerning at typical doses of 1–2 g daily. Individuals on anticoagulation therapy should inform their prescribing physician before starting fish oil supplementation and may require more frequent INR monitoring to ensure their anticoagulation remains within the therapeutic range.
How does mackerel oil reduce inflammation at the molecular level?
EPA and DHA from mackerel oil incorporate into cellular membrane phospholipids, replacing arachidonic acid as a substrate for cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX), which reduces production of pro-inflammatory prostaglandin E2, thromboxane A2, and leukotriene B4 while promoting synthesis of less potent 3-series prostaglandins and specialized pro-resolving mediators including resolvins, protectins, and maresins. Simultaneously, DHA activates GPR120 receptors on macrophages to inhibit NF-κB and TAK1 signaling, and both EPA and DHA bind PPARα/γ nuclear receptors to transcriptionally downregulate inflammatory cytokine genes including TNF-α, IL-6, and IL-1β.
What is the recommended daily dose of mackerel oil for heart health?
No mackerel-oil-specific clinical dosing guidelines exist; recommendations are extrapolated from broader fish oil evidence, with cardiovascular authorities generally recommending 250–500 mg EPA+DHA daily for primary prevention in healthy adults and 1,000–4,000 mg EPA+DHA daily for individuals with established cardiovascular disease or hypertriglyceridemia. The landmark REDUCE-IT trial demonstrated significant cardiovascular event reduction (25% relative risk reduction) using 4 g/day of pharmaceutical-grade EPA, while triglyceride-lowering effects are dose-dependent and typically require 2–4 g EPA+DHA daily for clinically meaningful reductions of 15–30%.
Can I get enough omega-3 PUFA from eating mackerel instead of taking supplements?
A 100g serving of Atlantic mackerel provides approximately 2.3g of combined EPA and DHA, which can meet or exceed daily cardiovascular recommendations (250–500mg) in a single meal. However, mackerel consumption frequency, preparation methods (cooking can reduce PUFA content by 10–15%), and individual absorption rates vary, making supplementation a more reliable option for consistent dosing, particularly for those with limited access to fresh fish or dietary restrictions.
Is mackerel oil omega-3 supplement safe during pregnancy and breastfeeding?
Mackerel oil is generally recognized as safe during pregnancy and lactation at standard doses (1–3g daily) and may support fetal neurodevelopment via DHA accumulation in brain tissue. However, due to potential heavy metal concerns in some fish species and the need for individualized dosing during pregnancy, consultation with a healthcare provider is essential before supplementation.
What clinical evidence supports mackerel oil's effect on triglyceride levels and heart disease risk?
Multiple randomized controlled trials demonstrate that mackerel oil supplementation reduces fasting triglycerides by 20–35% and improves the triglyceride-to-HDL ratio, key markers inversely associated with cardiovascular mortality. Studies also show reductions in atherogenic index (0.72–0.93) and thrombogenic index (0.75–0.92) in mackerel oil-treated groups, with benefits typically appearing after 4–8 weeks of consistent supplementation at doses of 2–3g daily.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w omega-3-pufa-from-mackerel-oil-scomber-spp curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
